Interleukin-2 (IL-2): The Double-Edged Sword of Immune Regulation

Abstract

Interleukin-2 (IL-2) is a cytokine with core immunoregulatory functions, initially discovered for its ability to promote T cell proliferation and once referred to as T cell growth factor (TCGF). It plays a "double-edged sword" role in the immune system: it can activate effector T cells (Teff) and natural killer (NK) cells to combat tumors and infections, while also maintaining the function of regulatory T cells (Treg) to suppress excessive immune responses and prevent autoimmune damage.

I. Overview of IL-2: Origin, Structure, and Receptor System

IL-2 is primarily produced by activated CD4⁺ T cells, with smaller amounts secreted by CD8⁺ T cells and NK cells. It is a single-chain polypeptide with a molecular weight of approximately 15.5 kDa, exerting its effects through binding to specific receptors.

The IL-2 receptor (IL-2R) consists of three subunits: CD25 (α chain), CD122 (β chain), and CD132 (γ chain). Different combinations of these subunits form receptors with varying affinities and functions, serving as the molecular basis for IL-2's dose-dependent bidirectional regulation:

High-affinity receptor (αβγ trimer): Mainly expressed on Treg cells, with extremely high affinity for IL-2. Low-dose IL-2 preferentially activates this receptor, selectively expanding and enhancing Treg's immunosuppressive function.

Intermediate-affinity receptor (βγ dimer): Expressed on Teff, NK cells, and memory T cells. Higher concentrations of IL-2 are required for effective activation, promoting the proliferation and cytotoxic activity of these cells.

Low-affinity receptor (α chain monomer): Rarely involved in signal transduction, primarily serving as a buffer to regulate IL-2 bioavailability.

II. Core Mechanism: Dose-Dependent Bidirectional Immune Regulation

IL-2's biological effects highly depend on its local concentration, precisely regulating immune balance through the aforementioned receptors with varying affinities.

1. High-dose IL-2: Immune Activation

Clinically, high-dose IL-2 regimens aim to activate effector immune cells expressing intermediate-affinity receptors:

Activation of effector T cells: Promotes clonal proliferation and differentiation of Teff, enhancing their ability to produce cytotoxic molecules like perforin and granzymes, directly killing tumor cells or pathogen-infected cells.

Activation of NK cells: Enhances NK cell proliferation and antibody-dependent cellular cytotoxicity (ADCC), while promoting secretion of cytokines like IFN-γ, boosting innate antitumor immunity.

Clinical application: Based on this, high-dose IL-2 became the first approved immunotherapy for metastatic renal cell carcinoma and melanoma.

2. Low-dose IL-2: Immune Tolerance Induction

Low-dose IL-2 selectively acts on Treg cells expressing high-affinity receptors:

Expansion and enhancement of Treg function: Stabilizes expression of the key transcription factor FOXP3, promoting Treg proliferation and survival, thereby strengthening their ability to suppress autoreactive T cell activation.

Restoration of immune balance: Increases the Treg-to-conventional T cell (Tcon) ratio, suppressing excessive inflammatory responses.

Clinical application: This property makes low-dose IL-2 promising for treating autoimmune diseases (e.g., type 1 diabetes, systemic lupus erythematosus) and graft-versus-host disease (GVHD).

III. Downstream Signaling Pathways: The Command Network Determining Cell Fate

Upon binding to its receptors, IL-2 primarily activates three key downstream signaling pathways, with their activation levels and balance determining the final immune outcome:

JAK-STAT pathway (especially STAT5): The core pathway for Treg function maintenance. Low-dose IL-2 strongly activates the JAK1/JAK3-STAT5 axis via high-affinity receptors, upregulating genes like FOXP3 to sustain Treg's inhibitory phenotype.

PI3K-Akt pathway: Mainly mediates cell survival, growth, and metabolism. High-dose IL-2 significantly activates this pathway via intermediate-affinity receptors, promoting Teff and NK cell proliferation while inhibiting apoptosis.

MAPK/ERK pathway: Regulates cell activation and cytokine production, enhancing the immune response function of effector cells.

These pathways do not operate in isolation but exhibit crosstalk. For example, the relative activation strengths of JAK-STAT and PI3K-Akt pathways collectively determine whether the immune response tilts toward suppression (Treg-dominant) or activation (Teff-dominant).

IV. IL-2 and Related Diseases

Abnormal IL-2 signaling is closely linked to the pathogenesis, progression, and treatment of various diseases.

1. Malignancies

Renal cell carcinoma and melanoma: The tumor microenvironment often exhibits impaired IL-2 signaling or competitive IL-2 consumption by Treg cells, weakening antitumor immune responses. High-dose IL-2 monotherapy or combination with vaccines, histone deacetylase inhibitors (e.g., entinostat), or immune checkpoint inhibitors (e.g., PD-1/CTLA-4 antibodies) can significantly improve efficacy.

Neuroblastoma: IL-2 combined with anti-GD2 antibodies (e.g., dinutuximab) aims to enhance NK cell-mediated ADCC, but requires balancing efficacy with potential IL-2 toxicity.

2. Autoimmune and Transplantation-Related Diseases

Chronic GVHD: Patients often exhibit Treg quantity/function defects. Low-dose IL-2 therapy can effectively expand Tregs, restore immune balance, and improve clinical symptoms.

Autoimmune vasculitis/systemic lupus erythematosus: Low-dose IL-2 enhances Treg function, suppressing autoreactive T cells, showing promising disease control potential in clinical trials.

3. Infectious Diseases

HIV infection: HIV destroys CD4⁺ T cells, reducing IL-2 production. Although IL-2 supplementation can increase CD4⁺ T cell counts, large clinical trials have not demonstrated clear clinical benefits beyond standard antiviral therapy, limiting its therapeutic value.

V. Future Perspectives: Development of Novel IL-2 Therapies

Due to the narrow therapeutic window, short half-life, and complex "double-edged sword" nature of natural IL-2, current research focuses on developing novel IL-2 formulations to optimize efficacy and safety:

Engineered mutants: Alter IL-2 protein structure to reduce CD25 (α chain) binding, favoring activation of βγ receptor-expressing effector cells over Tregs, enhancing selectivity in antitumor therapy.

PEGylation or Fc fusion proteins: Extend IL-2's in vivo half-life, reducing dosing frequency.

Bispecific molecules: Design fusion proteins targeting both IL-2 and tumor-associated antigens, enriching IL-2 effects in the tumor microenvironment to increase local concentration and reduce systemic toxicity.

Combination strategies with other immunotherapies: Synergize with checkpoint inhibitors, cancer vaccines, or adoptive cell therapies to enhance antitumor effects.

Summary

Interleukin-2 is a central hub molecule in the immune system's finely tuned regulatory network. Its bidirectional immunoregulatory properties present both challenges and unique opportunities for treating immune imbalance-related diseases. From early high-dose bolus therapies to low-dose tolerance induction strategies, and now to novel drug development based on structural biology and synthetic immunology, deepening understanding of IL-2 biology continues to drive innovation in tumor immunotherapy and autoimmune disease treatment. In the future, safer and more precise IL-2-related therapies may bring hope to more patients.